白蛋白结合型紫杉醇治疗晚期耐药复发卵巢癌的疗效及安全性

发布时间：2018-03-08 08:52

本文选题：白蛋白　切入点：紫杉醇　出处：《中国老年学杂志》2017年16期 　论文类型：期刊论文

【摘要】：目的探讨白蛋白结合型紫杉醇(nab-p)治疗晚期耐药复发卵巢癌的疗效及耐受性。方法对2012年1月至2015年12月在吉林大学第一医院接受以nab-p为基础化疗方案的21例复发/难治性晚期卵巢癌患者进行回顾性临床分析。均为经多线药物治疗后复发的患者,给予nab-p 120 mg/m2,第1、8天,联合或不联合卡铂[卡铂曲线下面积(AUC)=4~5,第2天]静脉滴注,21 d为1个疗程。结果 21例患者均可评估疗效,无完全缓解病例,部分缓解13例,疾病稳定5例,疾病进展3例。21例患者接受nab-p为基础化疗方案的有效率为61.9%(13/21),CA125完全缓解率为28.6%(6/21);铂类敏感者的有效率为88.9%(8/9),铂类耐药者的有效率为41.6%(5/12),两者差异无统计学意义(P0.05)。治疗过程中1例出现了肝功能1级异常,2例出现了2级粒细胞减少不伴发热,2例出现Ⅱ度外周神经病变。未记录到剂量减少或治疗中断。结论 nab-p在先前接受过多线药物治疗的复发/难治性卵巢癌患者中表现出较好的疗效性及耐受性。
[Abstract]:Objective to investigate the efficacy and tolerance of albumin binding taxol nab-p in the treatment of advanced drug-resistant recurrent ovarian cancer. Methods from January 2012 to December 2015, 21 patients received chemotherapy based on nab-p in Jilin University first Hospital. / retrospective clinical analysis of patients with refractory advanced ovarian cancer. Nab-p 120 mg / m ~ (2), day 1 ~ 8, combined or not carboplatin [area under carboplatin curve] intravenously dripping for 21 days was a course of treatment. Results 21 patients could evaluate the curative effect, none of them had complete remission, 13 had partial remission. The disease was stable in 5 cases, The effective rate of nab-p based chemotherapy regimen was 61.9%, and the complete remission rate of CA125 was 28.66.21%. The effective rate of platinum-sensitive patients was 88.9% and that of platinum-resistant patients was 41.6% / 122.There was no significant difference between the two groups in the course of treatment. Grade 1 abnormal liver function was found in 1 case and grade 2 granulocytopenia without fever occurred in 2 cases. No dose reduction or interruption of treatment was recorded in 2 cases. Conclusion nab-p was previously given multiple line drugs. Treatment of recurrent / refractory ovarian cancer patients showed good efficacy and tolerance.
【作者单位】：吉林大学第一医院肿瘤中心;
【分类号】：R737.31

【相似文献】